Day 0 "Vaccine Efficacy"
Phase III Pfizer controls vs. Healthcare personnel in northern California
Phase III clinical trials for COVID mRNA shots involved an efficacy measurement that didn’t start counting symptomatic COVID infections until at least a week after the second dose.
But using the bottom half of Table 2 in the 6-month Pfizer trial report, you can surmise the baseline symptomatic infection risk from the placebo group:
Placebo symptomatic case incidence was 169 per 2,345 person-years of follow-up = 139 weekly symptomatic cases per 100,000.
Using the baseline risk of 139 weekly symptomatic cases per 100,000 (139 per 100,000 person-weeks), you could compare it to the rate for healthcare personnel who were “ever-jabbed” in northern California: 48 weekly symptomatic infections per 100,000.
The effectiveness formula looks like this:
(risk in control group - risk in treated group)
_________________________________________ * 100 [%]risk in control group
When you plug the numbers in, that’s an effectiveness of 65%, much different from the 95% that Pfizer reported. Even more disturbing is that most of the symptomatic infections in healthcare personnel were within 14 days of getting jabbed — indicating that the jabs were increasing the chance to develop a symptomatic infection.
Worse than Pfizer’s Control Group
If you restricted the time-window to just the first few weeks post-jab, which is “somewhat” unfair but still revealing, then jabbed healthcare personnel got symptomatic COVID at higher rates than the Pfizer control group.
Of the 151 symptomatics that recorded the date of symptom onset, 75% of them had symptoms by Day 18 after Jab #1 (middle graph in second link below). Extending this proportion to all 157 symptomatic cases would make for 118 symptomatic cases in the first 18 days.
Because 22,729 healthcare personnel got at least one dose, once the observation is arbitrarily restricted to the first 18 days, it would involve 58,446 person-weeks and 118 symptomatic cases:
202 weekly symptomatic cases per 100,000 (a 45% higher rate than Pfizer controls)
Critics and detractors will rush to say how the healthcare personnel were observed from December 2020 to March 2021, while the Pfizer trial time window was shifted earlier than that, before the winter peak.
For once, the critics and detractors would have a point. But still, 45% higher symptomatic case rates than no “vaccine” at all?
Really? It still seems preposterous.
Reference
[jabbed healthcare personnel got 48 weekly symptomatic infections per 100,000 over a 100-day time-window] — Jacobson KB, Pinsky BA, Rath MEM, Wang H, Miller JA, Skhiri M, Shepard J, Mathew R, Lee G, Bohman B, Parsonnet J, Holubar M. Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. medRxiv [Preprint]. 2021 Apr 24:2021.04.14.21255431. doi: 10.1101/2021.04.14.21255431. Update in: Clin Infect Dis. 2021 Jun 17;: PMID: 33907767; PMCID: PMC8077590. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077590/
Evolution of symptomatic infection from above (middle graph): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077590/figure/F1/
[Pfizer control group got 139 weekly symptomatic cases per 100,000; Table 2, bottom half] — Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745181/
.
The Vaccinated Have Been PUNKED
For Believing
The Unbelievable.